171,447 Teladoc Health, Inc. $TDOC Shares Sold by Corient Private Wealth LP

Key Points

• Corient Private Wealth LP cut its Teladoc Health stake by 62.8% in the second quarter, selling 171,447 shares and retaining 101,556 shares valued at approximately $861,000.
• Analyst sentiment remains mixed, with five Buy, ten Hold and one Sell rating. The consensus is Hold, with an average price target of $7.54.
• Teladoc reported a quarterly loss of $0.21 per share, better than the $0.25 expected, while revenue of $606.93 million fell short of estimates and declined 4% year over year.

Corient Private Wealth LP trimmed its holdings in shares of Teladoc Health, Inc. (NYSE:TDOC - Free Report) by 62.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 101,556 shares of the health services provider's stock after selling 171,447 shares during the period. Corient Private Wealth LP owned approximately 0.06% of Teladoc Health worth $861,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Renaissance Technologies LLC increased its position in Teladoc Health by 1.3% during the 1st quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider's stock valued at $44,066,000 after buying an additional 107,400 shares in the last quarter. Monaco Asset Management SAM purchased a new position in Teladoc Health during the second quarter valued at $26,864,000. Pale Fire Capital SE boosted its holdings in Teladoc Health by 74.8% in the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider's stock worth $18,522,000 after acquiring an additional 1,454,288 shares in the last quarter. Quantinno Capital Management LP boosted its holdings in Teladoc Health by 128.0% in the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider's stock worth $14,287,000 after acquiring an additional 1,471,631 shares in the last quarter. Finally, Freestone Grove Partners LP purchased a new stake in shares of Teladoc Health in the second quarter worth $7,338,000. 76.82% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TDOC has been the topic of a number of research reports. Citigroup dropped their price objective on shares of Teladoc Health from $11.00 to $7.50 and set a "neutral" rating on the stock in a report on Monday, August 3rd. Bank of America upped their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the company a "buy" rating in a report on Tuesday, July 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Finally, Canaccord Genuity Group dropped their price target on shares of Teladoc Health from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $7.54.

Teladoc Health Stock Performance

TDOC opened at $6.10 on Monday. Teladoc Health, Inc. has a fifty-two week low of $4.40 and a fifty-two week high of $9.89. The firm's fifty day moving average is $6.90 and its 200 day moving average is $6.85. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -6.16 and a beta of 2.12.

Teladoc Health (NYSE:TDOC - Get Free Report) last issued its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. The company had revenue of $606.93 million during the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. Teladoc Health's quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300--0.200 EPS and its FY 2026 guidance at -1.000--0.750 EPS. On average, equities research analysts predict that Teladoc Health, Inc. will post -0.92 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Charles III sold 17,805 shares of the business's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $6.10, for a total value of $108,610.50. Following the transaction, the chief executive officer directly owned 465,535 shares of the company's stock, valued at approximately $2,839,763.50. The trade was a 3.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.70% of the company's stock.

Teladoc Health Company Profile

Teladoc Health, Inc is a virtual healthcare company that provides telehealth services and technology to individuals, employers, health plans, health systems and other organizations. Its platform enables patients to connect with healthcare professionals remotely through phone, video and digital tools, supporting access to medical care across a range of specialties.

The company's offerings include general medical consultations, mental health services through BetterHelp, expert medical opinions, chronic condition management and digital health programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.